Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Video

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the unmet need addressed with the addition of NOV202 to olaparib (Lynparza) in BRCA1/2-mutated prostate cancer.

Preclinical findings, which were presented during the 2021 EAU Congress, aimed to evaluate whether NOV202, a vascular-disrupting agent, could increase the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer–based xerograph mouse models with BRCA1/2 mutations, Sereti says.

This research addresses an urgent clinical need, which is to develop novel, combinational therapeutic strategies that can improve the efficacy observed with single-agent PARP inhibitors, prevent or overcome resistance to PARP inhibitors, and expand the population that may benefit from treatment with PARP inhibitors, Sereti concludes.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS